Five-day aprepitant versus fosaprepitant in patients receiving cisplatin
the ONA take:
Single administration of fosaprepitant meglumine was no less effective than 5-day administration of aprepitant for preventing acute and delayed nausea and vomiting symptoms occurring after administration of cisplatin-based chemotherapy regimens, a new study published online in the journal Supportive Care in Cancer has shown.
For the study, researchers sought to compare the impact of 5-day aprepitant with single administration of fosaprepitant meglumine, the intravenous formulation of aprepitant, on the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic cisplatin-based chemotherapy.
Researchers enrolled 101 patients who received chemotherapy for esophageal, gastric, head and neck, or lung cancer with a regimen containing cisplatin 60 mg/m2 or higher. Participants were randomly assigned to receive either aprepitant for 5 days or one dose of fosaprepitant meglumine.
Results showed no significant differences in the complete response rate or the complete control rate over the 7-day period following the first cisplatin administration.
Single administration of fosaprepitant meglumine no less effective for preventing acute and delayed nausea and vomiting symptoms.
Sign Up for Free e-newsletters
- Scalp Cooling With Dignicap May Reduce Alopecia During Chemotherapy for Breast Cancer
- Evolution of HER2-Positive Breast Cancer: Yesterday, Today, and Tomorrow
- Dedicated End-of-Life Education Program Improves Nurses' Care, Patient and Family Satisfaction
- Reflexology, Aromatherapy May Reduce Pain, Anxiety of Brachytherapy for Cervical Cancer
- Accurate Understanding of Capacity May Improve Workflow, Efficiency in Infusion Suite
- Multimodal Follow-up Improved Postradiotherapy Sexual Health in Lower GI, Gynecologic Cancers
- Lung Cancer Screening Program In Ambulatory Clinics May Improve Detection Rates
- Nursing Practice Change Improved Chemo Administration, But Old Habits Die Hard
- Simple Adjustment Key to Paclitaxel Infusion Protocol That Reduced Hypersensitivity Reactions
- Online Program Aims to Assist With Clinical Trial Enrollment for Hematologic Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|